louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02044926: Intraductal Papillary Mucinous Neoplasm With Malignant Change
Official title: Intraductal Papillary Mucinous Neoplasm (IPMN) With Malignant Change: Prospective Study to Assess Diagnostic Performance of CT and Magnetic Resonance Imaging (MR) According to International Consensus Guidelines 2012
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: IPMN
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2014-01-24
Enrollment: 54
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patents who are suspected to have pancreas IPMN by clinicians or imaging studies

Brief summary: Purpose:

To investigate diagnostic performance of CT and MR in intraductal papillary mucinous neoplasm with malignant change according to international consensus guidelines 2012.

Hypothesis: According to 2012 consensus guidelines, enhanced solid component and main pancreatic duct size of larger than 10 mm will be significant.

Detailed description: 1. Purpose

   * To investigate diagnostic performance of CT and MR in intraductal papillary mucinous neoplasm with malignant change according to international consensus guidelines 2012
2. Enroll criteria

   * Patient who is suspected to have pancreas IPMN on imaging
   * Interval between imaging study and surgery is less than 2 months
   * Who is scheduled for surgery due to IPMN

Eligibility criteria: Inclusion Criteria:

* Patients who is suspected to have IPMN by imaging study or clinician
* Time interval between imaging study and surgery less than 2 months

Exclusion Criteria:

* Patients who have pathology results not by surgery
* Who is less than 20 years old
* Who cannot voluntarily agree study design

Primary outcomes:
measure: Imaging predictor of malignant IPMN of the pancreas
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Jae Ho Byun
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02397226: Lower Limb Venous Insufficiency and the Effect of Radiofrequency Treatment Versus Open Surgery
Official title: Lower Limb Venous Insufficiency and the Effect of Radiofrequency Treatment Versus Open Surgery. A 5-year Follow-up Using Duplex Ultrasound, Plethysmography, VCSS, AVVQ and EQ-5D
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Varicose Veins
Venous Insufficiency
Keywords: Radiofrequency ablation
Plethysmography
Duplex ultrasound
High ligation/stripping
Lead sponsor: University Hospital, Linkoeping
Sponsor class: OTHER
First posted: 2015-03-24
Enrollment: 198
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 200 patients with insufficient great saphenous veins will be randomized to either radiofrequency ablation or high ligation/stripping (open surgery). They will be examined according to standardized examination protocol Venous Clinical Severity Score (VCSS), with duplex ultrasound and plethysmography pre- and postoperatively (1-month, 1-, 3 and 5 years). They are to fill questionnaires EuroQol 5 Dimensions (EQ-5D) and disease specific Aberdeen Varicose Vein Questionnaire (AVVQ).


Eligibility criteria: Inclusion Criteria:

* Insufficient great saphenous vein
* Possible to treat with both radiofrequency ablation and high ligation/stripping
* Clinical Etiological Anatomical Pathophysiological score (CEAP) C2-C6

Exclusion Criteria:

* Previous intervention in the affected leg
* Insufficient accessory branch origin close to the great saphenous vein estuary in the femoral vein.
* Small saphenous vein insufficiency with diameter \>6 mm and/or flow \>100ml/min
* Patient that is not able to perform plethysmography

Primary outcomes:
measure: Number of treated veins with recanalization using duplex.
timeFrame: 5 years
measure: Number of treated limbs with neovascularization using duplex and/or plethysmography.
timeFrame: 5 years
measure: Prediction of treatment outcome using plethysmography with superficial shut-down.
timeFrame: 1 month postoperatively
Secondary outcomes:
measure: VCSS score
timeFrame: 5 years
measure: AVVQ score
timeFrame: 5 years
measure: EQ-5D score
timeFrame: 5 years
Other outcomes:
Locations:
city: Linköping
country: Sweden
facility: University Hospital Linköping
state: Östergötland
city: Norrköping
country: Sweden
facility: Vrinnevisjukhuset
state: Östergötland
Study officials:
affiliation: Linkoeping University
name: Helene Zachrisson, Associate Professor, MD
role: STUDY_CHAIR
affiliation: Linkoeping University
name: Oskar Nelzén, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nelzen POE, Skoog J, Oster M, Zachrisson H. Impact on venous haemodynamics after treatment of great saphenous vein incompetence using plethysmography and duplex ultrasound. Phlebology. 2020 Aug;35(7):495-504. doi: 10.1177/0268355519898952. Epub 2020 Jan 20.
Clinical trial NCT01337726: Combined Illness Management and Psychotherapy in Treating Depressed Elders
Official title: Combined Illness Management and Psychotherapy in Treating Depressed Elders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Heart Failure
Chronic Obstructive Pulmonary Disease
Keywords: Depression
Heart Failure
Chronic Obstructive Pulmonary Disease
Quality of Life
Functional Impairment
Lead sponsor: University of Iowa
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2011-04-19
Enrollment: 226
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to test a program developed to help patients with chronic heart or lung problems take care of themselves and cope with their illness or limitations.


Eligibility criteria: Inclusion Criteria:

* Age 55 years or older
* Diagnosis of Heart Failure or COPD
* Depressive symptoms indicated by a BDI-II score of 10 or higher
* Functional impairment

Exclusion Criteria:

* Current psychotherapy
* Cognitive Impairment
* Psychiatric diagnosis
* Active suicidal thoughts
* Significant vision or hearing impairment
* Residence in long term care facility

Primary outcomes:
measure: Reduction in depressive symptoms
timeFrame: 10 weeks
Secondary outcomes:
measure: Improvement in quality of life/functioning
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: Iowa City VA Health Care System
state: Iowa
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
Study officials:
affiliation: University of Iowa
name: Carolyn L. Turvey, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05894226: Functional and Sexual Outcomes After Laparoscopic Ventral Mesh Rectopexy for Complex Rectocele
Official title: Functional and Sexual Outcomes After Laparoscopic Ventral Mesh Rectopexy for Complex Rectocele
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Rectocele
Obstructive Defecation Syndrome
Keywords: Anterior rectocele
laparoscopic ventral mesh rectopexy
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2023-06-08
Enrollment: 15
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The ideal surgical strategy for treating complex rectocele remains a topic for debate, with the transanal, transperineal, and transvaginal approach and the abdominal approach being at conflict with one another. While the transvaginal repair is more popular among gynecologists, the trans abdominal approach has become increasingly common among colorectal surgeons, in part due to the rising demand for minimally invasive surgery.

Detailed description: For the treatment of rectoceles and ODS in general, the laparoscopic method has recently come to light as a promising alternative.

Laparoscopic ventral mesh rectopexy (LVMR) was originally described for the management of rectal prolapse. However, It was also recommended with encouraging results for the treatment of large symptomatic rectocele.

The present study aims to evaluate the safety and efficacy of LVMR for complex rectocele.

Eligibility criteria: Inclusion Criteria:

* multiparous female patients.
* aged between 30 and 60 years
* who were diagnosed with complex anterior rectocele- more than 3cm after failed medical treatment- with history of either vaginal delivery or caesarian section.
* complex rectocele was one having any of the following features: size \> 3 cm in diameter, associated enterocoele or internal rectal prolapse

Exclusion Criteria:

* paradoxical contraction of puborectalis muscle (anismus),
* complete external rectal prolapse
* fecal incontinence
* other benign anal conditions
* those who are unfit for surgery due to associated severe co-morbidities

Primary outcomes:
measure: changes in the Wexner constipation score
timeFrame: 6 months
Secondary outcomes:
measure: sexual function changes
timeFrame: 6 months
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Ahmad
Study officials:
References:
Clinical trial NCT01913626: Assessing the Efficiency of Cognitive Group Therapy for Patient With Subjective Memory Complains Using the WebNeuro System From Brain Resource(BRC)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Subjective Memory Complains
Keywords: subjective memory complains
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2013-08-01
Enrollment: 10
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: assessing the Efficiency of cognitive group therapy for patients with subjective memory complains, using the neuropsychological computerized assessment of WebNeuro by Brain resource (BRC).

Detailed description: the study includes patients with subjective memory complains - who are concerned about having memory problems, that passed successfully the conventional basic cognitive assessment and who are not demented.

the patients were referred to our occupational therapy clinic for cognitive group therapy.

the aim of the study is to assess the efficiency of such therapy, using the neuropsychological computerized assessment of WebNeuro by Brain resource (BRC). the computerized assessment last 40 minutes and provide information about different cognitive aspects compared to a norm according to age, sex and education.

each patient will pass the neuropsychological computerized assessment twice: at the beginning of the study and after participating in the cognitive group therapy.

the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.

each individual will be his one control, we will compare the patient achievements in the different cognitive aspects before and after the cognitive intervention.

our hypothesis is that the cognitive group therapy will improve the participants achievements in the neuropsychological computerized assessment.

Eligibility criteria: Inclusion Criteria:

* age 50 years old and more
* 8 years of education
* know reading and writing in hebrew
* know how to use the computer

Exclusion Criteria:

* neurologic or psychiatric conditions: apraxia, aphasia, depression, brain tumor

Primary outcomes:
measure: the patient achievements in the different cognitive aspects assessed by the computerized neuropsychological assessment of WebNeuro by Brain resource (BRC)
timeFrame: 10 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: geriatric rehabilatation department , Meir medical center
Study officials:
References:
Clinical trial NCT03702426: Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis
Official title: Comparison of the Efficacy of Granulocyte - Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis - A Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spontaneous Bacterial Peritonitis
Lead sponsor: Institute of Liver and Biliary Sciences, India
Sponsor class: OTHER
First posted: 2018-10-11
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: -Consecutive patients of decompensated cirrhosis of any etiology, presenting to the Institute of Liver and Biliary Sciences hospital with spontaneous bacterial peritonitis will be evaluated


Eligibility criteria: Inclusion Criteria:

* Age 18 - 70years
* Patients of decompensated liver cirrhosis who present with spontaneous bacterial peritonitis (Presence of more than 250 neutrophils per cc of ascitic fluid, in the absence of a surgical abdomen, in the presence of decompensated cirrhosis and portal hypertension) that has responded to standard medical care.

Exclusion Criteria:

* Allergic to quinolones
* Advanced HCC (Hepatocellular Carcinoma)
* Post liver transplant
* HIV (Human Immunodeficiency Virus) positive patients
* Patients on immunosuppressive therapy
* Pregnancy
* Acute Liver Failure
* History of hematological malignancy or bone marrow transplantation
* No informed consent

Primary outcomes:
measure: Spontaneous Bacterial Peritonitis on secondary prophylaxis in both groups
timeFrame: 6 Month
Secondary outcomes:
measure: Survival in both groups after development of SBP (Spontaneous Bacterial Peritonitis ).
timeFrame: 4 weeks
measure: Survival in both groups after development of SBP (Spontaneous Bacterial Peritonitis ).
timeFrame: 12 weeks
measure: Survival in both groups after development of SBP (Spontaneous Bacterial Peritonitis ).
timeFrame: 24 weeks
measure: Survival in both groups after development of SBP (Spontaneous Bacterial Peritonitis ).
timeFrame: 48 weeks
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Institute of Liver & Biliary Sciences
state: Delhi
Study officials:
References:
Clinical trial NCT05478226: ADAMTSL4 in Idiopathic Pulmonary Hypertension and CTEPH
Official title: ADAMTSL4 in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Hypertension
Lead sponsor: First Affiliated Hospital of Chongqing Medical University
Sponsor class: OTHER
First posted: 2022-07-28
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with IPAH and CTEPH compliance with 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Brief summary: ADAMTSL4 (A disintegrin and metalloproteinase with thrombospondin motifs like) is a member of the ADAMTSL family. ADAMTSL4 is one of the family of 7 ADAMTS-Like proteins, themselves part of the Thrombospondin type 1 repeat (TSR) superfamily of proteins. These 7 proteins are divided into two distinct clades, of which ADAMTSL4 and ADAMTS-Like 6 form part of one clade, differing from ADAMTS-Like 1, ADAMTS-Like 3 and ADAMTS-Like 7 by lacking immunoglobulin repeat regions. ADAMTSL4 is widely expressed in brain, colon, heart, kidney, liver, lung, pancreas and spleen, yet, its precise role is unclear. in addition, ADAMTSL4 protein high expression to the medial layer of the arterial wall, and medial vascular smooth muscle cells specifically.

Detailed description: The objectives of the present study aimed to confirm ADAMTSL4 levels in the proteomics between healthy control population and patients with IPAH，to analyze the expression levels of ADAMTSL4 between patients with IPAH and CTEPH, and to investigate whether serum levels of ADAMTSL4 might be used as biomarkers of disease severity in these patient populations.

Eligibility criteria: Inclusion Criteria:

- Healthy people，patients with IPAH，patients with CTEPH

Exclusion Criteria:

- tumour，infection，Pregnancy, suckling period， Mental disorders，

Other types of PAH except CTEPH and IPAH

Primary outcomes:
measure: Association of clinic index and ADAMTSL4 expression level
timeFrame: 2018-2022
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: the First Affiliated Hospital, Chongqing Medical University
state: Chongqing
Study officials:
affiliation: First Affiliated Hospital of Chongqing Medical University
name: Wei Huang, Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02338726: Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study
Official title: Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urinary Incontinence
Quality of Life
Keywords: urinary incontinence
pelvic floor
quality of life
elderly women
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2015-01-14
Enrollment: 143
Sex: FEMALE
Minimum age (years): 64
Maximum age (years): 66
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 100-130 women aged 64-66 years in one single municipality

Brief summary: To assess pelvic floor symptoms and quality of life in elderly women.

Detailed description: The aim is to assess pelvic floor symptoms and quality of life in elderly women. The study is conducted as population-based in 100-130 women at the age of 64-66 years. All study objects are examined gynecologically and with vaginal ultrasound. Subjective symptoms are evaluated with validated questionnaires concerning pelvic floor symptoms, sexual symptoms and quality of life. This is a pilot study before a larger scale population-based study.

Eligibility criteria: Inclusion Criteria:

* All women in one municipality aged 64-66 years who are willing to participate in the study.

Exclusion Criteria:

* Persons under guardianship or who does not understand the used questionnaires.

Primary outcomes:
measure: Validity of questionnaires to find pelvic floor symptoms
timeFrame: An average of 4 weeks, from returning the questionnaires to gynecological examination
Secondary outcomes:
measure: Quality of life in elderly women
timeFrame: ◦Measures assessed at the time when questionnaires are filled in, one time point
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku University Hospital
Study officials:
affiliation: Turku University Hospital
name: Virpi Rantanen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03491826: Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM)
Official title: Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM) at AIN Shams Maternity Hospital: A Retrospective Analysis of Last Five Years Admissions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Premature Rupture of Membrane
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
Collaborators: name: Hend Mostafa Hussein Salem
First posted: 2018-04-09
Enrollment: 1011
Sex: FEMALE
Minimum age (years): 24
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: pregnant female with history of rupture membrane

Brief summary: The aim of this study is to compare fetal and maternal outcome in cases of PPROM before 34 weeks versus after 34 weeks.

Detailed description: The data will be retrieved from the archival files and analyzed

Eligibility criteria: Inclusion Criteria:

* rupture of membrane

Exclusion Criteria:

* medical disorder

Primary outcomes:
measure: maternal mortality
timeFrame: up to 48 hours after delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr El Ainiy Hospital
Study officials:
References:
Clinical trial NCT00947726: Ceramide Containing Multivesicular Emulsion Application . . .
Official title: Ceramide Containing Multivesicular Emulsion Application as a Skin Hydration Treatment for Feet of Subjects With Non-insulin Dependent Diabetes Mellitus.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Foot Transepidermal Water Loss in Patients in NIDDM
Foot Dryness in Patients With NIDDM
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor class: NIH
First posted: 2009-07-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: We believe that using a ceramide based foot cream two times a day for two weeks will prevent water loss and overall foot dryness in patients with non-insulin dependent diabetes.


Eligibility criteria: Inclusion Criteria:

* \>18 years of age
* non insulin-dependent diabetes
* moderate to severe xerosis of both feet \[a score of at least 4 on a scale of 0 (normal) to 8 (deep fissuring)\]
* capable of understanding and signing consent form

Exclusion Criteria:

* history of ichthyosis vulgaris
* known hypersensitivity to the topical product used in the study
* previous use of high potency steroids (class I and II) in past 2 week
* presence of acute skin disease or infection, such as vasculitis or cellulitis
* presence of foot ulcer
* evidence of gangrene

Primary outcomes:
measure: Decrease transepidermal water loss and foot dryness in study subjects.
timeFrame: 5 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: